European Leukemia Trial Registry
Trial: ALL Forodesin in T-ALL

More Details
Title Forodesin-Hydrochlorid (BCX-1777) in progressive T-Cell Leukemia
Scientific Title A Open-Label, Multi-Center Phase II Repeat-Dose Study of Forodesin-Hydrochlorid (BCX-1777)-Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesin-Hydrochlorid (BCX-1777) Use
Short Title ALL Forodesin in T-ALL
Trialgroup GMALL
Type of Trial multicentric
Disease Acute lymphoblastic leukemia(ALL) T-LBL
Age >= 18 years
Status Closed
Start of Recruitment 21.06.2005
Leader Hoelzer, Prof. Dr. med., Dieter

Study Physician
Gökbuget, Dr. med., Nicola
Tel: +49 (0)69 6301-6366
Fax: +49 (0)69 6301- 7463

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 07.07.2006 Anja Hellenbrecht
changed 13.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |